Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis

Yao, Zi-xiang; Lü, Linyuan; Wang, Ruijue; Jin, Liangbin; Liu, Shengchun; Li, Hongyuan; Ren, Guosheng; Wu, Kainan; Wang, Delin; Kong, Lingquan

doi:10.1007/s12032-013-0798-y

Cited by 60 publications

(48 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several detailed studies have documented small differences in the immunohistochemical expression of epithelial standard biomarkers [estrogen receptor (ER), progesterone receptor (PR), HER-2, p53, and Ki-67] between primary tumors and their paired LNMs. 10,11 Therefore, evaluating whether primary breast and matched metastatic lymph nodes differ in their specific fibroblasts biomarkers may help us understand the biological processes involved in the survival, the growth, and the adaptation to a foreign environment. To date, the few preliminary studies that compared differences in the expression of specific fibroblast-related biomarkers indicate that the lymph node stromal cells involved are metabolically active and express proteases, favoring tumor growth and migration.…”

mentioning

confidence: 99%

Breast Carcinoma–associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis

Mundim

Pasini²,

Nonogaki

et al. 2016

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

This study sought to understand the role of breast carcinoma-associated fibroblasts in the progression of cancer cells into lymph nodes. We compared fibroblasts of primary tumors and matched the involved lymph nodes to select fibroblast activation markers, namely α-smooth muscle actin (α-SMA), S100A4, and vimentin, as well as to determine the frequency of transforming growth factor β1, a pleiotropic cytokine that induces the differentiation of fibroblasts to myofibroblasts, and its downstream effectors: CXCR4 and p-AKT. We disposed samples of 80 primary invasive ductal carcinomas and matched the involved lymph nodes from 43 cases into 3 tissue microarrays, and analyzed stromal and tumor epithelial cells separately by immunohistochemistry. Control uninvolved lymph nodes were analyzed by whole-tissue sections. Cancer-associated fibroblast in lymph nodes with macrometastasis expressed similar profiles of vimentin, α-SMA, and S100A4 as those found in primary tumors. Cancer-associated fibroblast were uniformly estrogen receptor, progesterone receptor, HER-2, Ki-67, and p53 negative, but expressions of transforming growth factor β1 (TGFβ1), CXCR4, and p-AKT staining (62.3%, 52.4%, 65%, respectively) were equivalent between primary and lymph node metastasis (LNM) fibroblasts. A significant coexpression of TGFβ1 with p-AKT and CXCR4 in LNMs suggested the involvement of these proteins with TGFβ1 signaling. These biomarkers, including α-SMA and S100A4, were negative in fibroblasts of cancer-free lymph nodes, with the exception of vimentin. Our finding that expressions of biological markers were similar in fibroblasts of the primary tumors and in matched LNMs, but were absent in cancer-free lymph nodes, supports the assumption that the lymph node stroma mimics the microenvironment observed in primary tumors.

show abstract

mentioning

confidence: 99%

Breast Carcinoma–associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis

Mundim

Pasini²,

Nonogaki

et al. 2016

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

show abstract

“…Patients who have not undergone examination of metastatic tumor biomarkers might also be receiving treatment that is not necessary. Equally, increases in ER and HER2 in the relapse setting would make patients eligible for endocrine therapy or trastuzumab treatment and potentially lead to tumor response and prolonged survival in some patients [23]. The National Comprehensive Cancer Network panel recommends that metastatic disease at presentation or the first recurrence of disease should be biopsied as part of the workup for patients with recurrent or stage IV disease, and the determination of ER, PR and HER2 status should be repeated in cases when it was previously unknown, negative or not overexpressed [23,24].…”

Section: Discussionmentioning

confidence: 99%

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Hou

Shen²,

Chaudhary³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

Objective: Changes in the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in metastatic breast carcinomas are frequently reported. We examined the change in the status of biomarkers in metastatic breast carcinomas. Study Design: This study cohort was composed of 137 metastatic breast carcinomas (58 surgical and 79 cytological specimens) with existing primary tumors during a study period from 2013 to 2015. Results: The overall change rates in metastases were 9, 21 and 6% for ER, PR and HER2, respectively. All changes were from positive in the primary tumor to negative in the metastases. The ER change rate was significantly higher in the cytological than in the surgical metastases. Six of 14 cytological metastases with positive HER2 in primary tumors showed a change in HER2 status, including 5 fluid specimens and 1 fine-needle aspiration (FNA); the other 8 had no change in HER2 status, and included 7 FNAs and 1 fluid specimen. Conclusion: The significant percentage of cases with a change in biomarker status supports the recommendation by the College of American Pathologists to test breast biomarkers in metastases. HER2 status change was mostly identified in fluid specimens; however, the small sample size in our cohort and the fact that HER2 fluorescence in situ hybridization was not performed may warrant further studies.

show abstract

“…The cell adhesion molecule E-cadherin (epithelial cadherin) is a member of the cadherin family of transmembrane glycoproteins that mediate calcium dependent homophilic cell-cell adhesion. E-cadherin acts as an invasion suppressor molecule [7,11,12]. Invasion is the hallmark of malignancy.…”

Section: Discussionmentioning

confidence: 99%

Relation between the expression of E-cadherin, p53,c-erb-B2 (HER-2/neu) and steroid receptors (ER, PgR) in invasive ductal breast carcinoma with axillary lymph node metastases

Kılınç

2015

MMJ

View full text Add to dashboard Cite

Relation between the expression of E-cadherin, p53,c-erb-B2 (HER-2/neu) and steroid receptors (ER, PgR) in invasive ductal breast carcinoma with axillary lymph node metastases Aksiller lenf nodu metastazlı invaziv duktal meme karsinomda E-cadherin, p53, c-erb-B2 (HER-2/neu) ve steroid reseptörleri (ER, PgR) ekspresyonu arasındaki ilişki Patients and Methods:We have investigated tumor samples from sixty patients with invasive ductal breast carcinoma. 30 of the patients had axillary lymph node metastases and 30 had no axillary lymph node metastases. Tumor tissues of these patients were evaluated by immunohistochemistry for E-cadherin, p53, c-erb-B2 (HER-2/neu) and steroid receptors (ER, PgR).Results: E-cadherin staining was not expressed in 39 patients (65%) with invasive ductal breast carcinoma. ER, PgR, p53, and c-erb-B2 signals were positive in 36 (60%), 26 (43.3%), 33 (55%), and 29 (48.3%) of the patients, respectively. PgR and c-erb-B2 expression was associated with lymph node metastases (p=0.009, p=0.001, respectively). No association was found between the reduced E-cadherin protein and age. The presence of E-cadherin was associated with axillary lymph node metastases and p53 (p<0.009, p<0.001, respectively). Conclusion:We found that, the p53 protein may play a role in regulation of E-cadherin protein expression in invasive ductal breast carcinomas with axillary lymph node metastases. Bulgular: İnvaziv duktal meme karsinomlu 60 hastanın 39'unda (%65) E-cadherin ile boyanma tesbit edilmedi. Sırasıyla ER, PgR, p53, ve c-erb-B2, 60 hastanın 36'ında (%60), 60 hastanın 26'ında (%43,3), 60 hastanın 33'ünde (%55), and 60 hastanın 29'unda (%48,3) pozitif boyanma görüldü. PgR ve c-erb-B2 boyanması lenf nodu metastazı ile ilişkili idi (sırasıyla, p=0,009, p=0,001). E-cadherin proteini ile yaş arasında ilişki görülmedi. E-cadherin ile lenf nodu metastazı ve p53 arasında ilişki görüldü (sırasıyla, p<0,009, p<0,001).Sonuç: p53 proteini E-cadherin protein ekspresyonu gösteren aksiller lenf nodu metastazlı invaziv duktal meme karsinomda bir role sahiptir.

show abstract

Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis

Cited by 60 publications

References 31 publications

Breast Carcinoma–associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis

Breast Carcinoma–associated Fibroblasts Share Similar Biomarker Profiles in Matched Lymph Node Metastasis

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Relation between the expression of E-cadherin, p53,c-erb-B2 (HER-2/neu) and steroid receptors (ER, PgR) in invasive ductal breast carcinoma with axillary lymph node metastases

Contact Info

Product

Resources

About